Clinical Trials
5 trialsNCT04557007 2026-01-29
Oncomabs
Oslo University Hospital
Terminated
NCT05078931 2025-07-30
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
Shanghai Chest Hospital
Phase 2 Active not recruiting
NCT06754644 2025-06-10
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT03562871 2022-04-21
IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC
IO Biotech
Phase 1/2 Completed
NCT04164745 2019-11-15
Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer
Peking Union Medical College Hospital
Phase 2 Unknown